Zusammenfassung
Unter dem Oberbegriff der chronischen myeloproliferativen Erkrankungen (CMPE) fassen wir
-
die chronische myeloische Leukämie (CML),
-
die Polycythaemia vera (PV),
-
die idiopathische Osteomyelofibrose (OMS) und
-
die essenzielle Thrombozythämie (ET)
zusammen. Die CMPE treten sporadisch auf, gehen somit auf erworbene und nicht auf angeborene klonale genetische Veränderungen zurück. In allen Fällen sind als Ausgangszellen pluripotente hämatopoetische Stammzellen anzunehmen.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Barosi G (1999) Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 17:2954–2970
Bench AJ, Nacheva EP, Champion KM, Green AR (1998) Molecular genetics and cytogenetics of myeloprolifearative disorders. Baillieres Clin Haematol 11:819–848
Ben Neriah Y, Daley GQ, Mes Masson AM, Witte ON, Baltimore D (1986) The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233:212–214
Bennett JM, Catovsky D, Daniel MT et al. (1994) The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposal by the French-American-British Cooperative Leukaemia Group. Br J Haematol 87:746–754
Berk D, Goldberg JD, Donovan PB, Fruchtman SM, Berlin MI, Wasserman LR (1986) Therapeutic recommendations in polycythemia vera based on polycythemia study group protocols. Semin Hematol 23:132–143
Blanchard KL, Gilliland DG, Bunn HF (1992) Clonality in myeloproliferative disorders. Am J Med Sci 304:125–130
Chissoe SL, Bodenteich A, Wang YF et al. (1995) Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. Genomics 27:67–82
Chronic Myeloid Leukemia Trialist’s Collaborative Group (1997) Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 89:1616–1620
Clift RA, Appelbaum FR, Thomas ED (1993) Treatment of chronic myeloid leukemia by marrow transplantation. Blood 82:1954–1956
Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824–830
Davis RL, Konopka JB, Witte ON (1985) Activation of the c-abl oncogene by viral transduction generates altered c-abl proteins with similar in vitro kinase properties. Mol Cell Biol 5:204–213
Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343–3356
Demory JL, Dupriez B, Fenaux P et al. (1988) Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood 72:855
Derderian PM, Kantarjian HM, Talpaz M (1993) Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med 94:69–74
Druker BJ, Sawyers CL, Kantarjian H et al. (2001a) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome. N Engl J Med 344:1038–1042
Druker BJ, Talpaz M, Resta DJ et al. (2001b) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037
Dudley JM, Westwood N, Leonard S, Eridani S, Pearson TC (1990) Primary polycythaemia: positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin 3 and alpha-interferon. Br J Haematol 75:188–194
Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM (1999) The biology of chronic myeloid leukemia. N Engl J Med 341:164–172
Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilliland DG (2001) Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase avctivity and induction of proteasome-mediated degradation. Mol Cel Biol 15:3547–3557
Gale RE, Hehlmann R, Zhang M-J et al. (1998) Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood 91:1810–1819
Ganesan TS, Rassool R, Guo A-P et al. (1986) Rearrangement of the bcr gene in Philadelphia chromosome-negative chronic myeloid leukemia. Blood 68:957–960
Gewirtz AM (1992) Therapeutic applications of antisense DNA in the treatment of human leukemia. Ann N Y Acad Sci 660:178–187
Gratwohl A, Hermans J, Goldman JM et al. (1998) Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet 352:1087–1092
Groffen J, Stephenson JR, Heisterkamp N, Klein A de, Bartram CR, Grosveld G (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36:93–99
Guardiolo P, Anderson JE, Bandini G et al. (1999) Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European group for blood and bone marrow transplantation. Blood 93:2831–2838
Guilhot F, Chastang C, Michallet M et al. (1997) Interferon alpha2b (IFN) combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 337:223–229
Haferlach T, Winkemann M, Nickenig C et al. (1997) Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May-Grunwald-Giemsa staining and fluorescence in situ hybridization techniques. Br J Haematol 97:99–106
Hansen JA, Gooley TA, Martin PJ et al. (1998) Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962–968
Harrison CN, Gale RE, Linch DC (1999) A large proportion of patients with a diagnosis of essential thrombocythemia does not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 93:417–422
Hasford J, Pfirrmann M, Hehlmann R et al. (1998) A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alpha. J Natl Cancer Inst 90:850–858
Hehlmann R (1998) A chance of cure for every patient with CML? N Engl J Med 338:980–982
Hehlmann R, Heimpel H, Hasford J et al. (1993) Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood 398:398–407
Heim S, Mitelman F (1995) Cancer cytogenetics. Wiley-Liss, New York
Heisterkamp N, Stephenson JR, Groffen J et al. (1983) Localization of the c-abl oncogene adjactent to a translocation breakpoint in chronic myelocytic leukaemia. Nature 306:239–242
Heisterkamp N, Jenster G, Hoeve J ten, Zovich D, Pattengale PK, Groffen J (1990) Acute leukaemia in bcr/abl transgenic mice. Nature 344:251–253
Hochhaus A, Reiter A, Skladny H et al. (1996) A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 88:2236–2240
Hochhaus A, Reiter A, Saussele S et al. (2000) Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 95:62–66
Johansson B, Fioretos T, Billström R, Mitelman F (1996) Aberrant cytogenetic evolution pattern of Philadelphia-positive chronic myeloid leukemia treated with interferon-α. Leukemia 10: 1134–1138
Kantarjian HM, Keating MJ, Talpaz M (1987) Chronic myelogenous leukemia in blast crisis: analysis of 242 patients. Am J Med 83:445–454
Kantarjian HM, Smith TL, O’Brien S, Beran M, Pierce S, Talpaz M (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 122:254–261
Kolb HJ, Schattenberg A, Goldman JM et al. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041–2050
Konopka JB, Watanabe SM, Witte ON (1984) An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37:1035–1042
Kramer A, Horner S, Wilier A et al. (1999) Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells. Proc Natl Acad Sci USA 96:2087–2092
Lange W, Cantin EM, Finke J, Dolken G (1993) In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA. Leukemia 7:1786–1794
Lengfelder E, Berger U, Hehlmann R (2000) Inteferon-α in polycythemia vera. Ann Hematol 79:103–105
Melo JV (1996) The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88:2375–2384
Melo JV, Myint H, Galton DAG, Goldman JM (1994) P190 BCR-ABL chronic myeloid leukemia: the missing link with chronic myelomonocytic leukemia? Leukemia 8: 208–211
Mitelman F (1993) The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma [Suppl 1] 11:11–15
Nanjangud G, Kadam PR, Saikia T et al. (1994) Karyotypic findings as an independent prognostic marker in chronic myeloid leukemia blast crisis. Leuk Res 18: 385–392
Nowell PC, Hungerford DA (1960) A minute chromosome in human granulocytic leukemia. Science 132:1497
Pane F, Frigeri F, Sindona M et al. (1996) Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 88:2410–2414 [published erratum appears in Blood 1997 Jun 1;89(11): 4244]
Petrides PE, Beykirch MK, Trapp O (1998) Anagrelide, a novel platelet lowering option in essential thrombocythemia: treatment experience in 48 patients in Germany. Eur J Hematol 61:71–76
Raanani P, Dazzi F, Sohal J et al. (1997) The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol 99:945–950
Radich JP, Gehly G, Gooley T et al. (1995) Polymerase chain-reaction detection for the bcr-abl fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implication in 346 patients. Blood 85:2632–2640
Rhee F van, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC (1996) pi90 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood 87:5213–5217
Reiter A, Skladny H, Hochhaus A et al. (1997) Molecular response of CML patients treated with interferon-α monitored by quantitative Southern blot analysis. Br J Haematol 97:86–93
Reiter A, Sohal J, Kulkarni S et al. (1998) Consistent fusion of ZNF198 to fibroblast growth factos receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood 92:1735–1742
Reiter A, Hehlmann R, Goldman JM, Cross NC (1999) The 8p11 myeloproliferative syndrome. Med Klin 94:207–210
Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290–293
Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330–1340
Schoch C, Schnittger S, Bursch S et al. (2002) Comparison of chromosome banding analysis, interphase- and hyper-metaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 16:53–59
Sill H, Goldman JM, Cross NC (1995) Homozygous deletions of the pl6 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 85:2013–2016
Sokal JE, Cox EB, Baccarani M et al. (1984) Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 63:789–799
Statistisches Bundesamt (1997) Statistisches Bundesamt: Sterbefälle nach Todesursachen in Deutschland. Einzelnachweis. Statistisches Bundesamt, Wiesbaden
Tefferi A (2000) Myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255–1263
Tefferi A, Solberg L, Silverstein MN (2000) A clinical update in polycythemia vera and essential thrombocythemia. Am J Med 109:141–149
Temerinac S, Klippel S, Strunck E et al. (2000) Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 95:2569–2576
Thiele J, Kvasnicka HM (2000) Polyglobulie versus Polycythemia vera. Pathologe 21:24–30
Virchow R (1845) Weisses Blut. Frorieps Notizen 36:151–156
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Haferlach, T., Schnittger, S., Schoch, C. (2003). Chronische myeloische Leukämie und andere chronische myeloproliferative Erkrankungen. In: Ganten, D., Ruckpaul, K., Schlegelberger, B., Fonatsch, C. (eds) Molekularmedizinische Grundlagen von hämatologischen Neoplasien. Molekulare Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59343-7_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-59343-7_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63941-8
Online ISBN: 978-3-642-59343-7
eBook Packages: Springer Book Archive